JP2016519673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519673A5 JP2016519673A5 JP2016503031A JP2016503031A JP2016519673A5 JP 2016519673 A5 JP2016519673 A5 JP 2016519673A5 JP 2016503031 A JP2016503031 A JP 2016503031A JP 2016503031 A JP2016503031 A JP 2016503031A JP 2016519673 A5 JP2016519673 A5 JP 2016519673A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- ring
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C*/C=C/[N+]C*C=C Chemical compound *C*/C=C/[N+]C*C=C 0.000 description 27
- CJDYFMIDIQXELO-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(C)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(C)CC1)=O CJDYFMIDIQXELO-UHFFFAOYSA-N 0.000 description 1
- XLZMWNWNBXSZKF-UHFFFAOYSA-N CC(C)N1CCOCC1 Chemical compound CC(C)N1CCOCC1 XLZMWNWNBXSZKF-UHFFFAOYSA-N 0.000 description 1
- LPZLRRWRPQSVBW-UHFFFAOYSA-O CC([NH2+]C=C)=CON Chemical compound CC([NH2+]C=C)=CON LPZLRRWRPQSVBW-UHFFFAOYSA-O 0.000 description 1
- IMFLCBVIUVVSKA-UHFFFAOYSA-O CC([NH2+]C=C)=CSN Chemical compound CC([NH2+]C=C)=CSN IMFLCBVIUVVSKA-UHFFFAOYSA-O 0.000 description 1
- JLAUIBFZZUVOBB-UHFFFAOYSA-N CCC(C)CCN Chemical compound CCC(C)CCN JLAUIBFZZUVOBB-UHFFFAOYSA-N 0.000 description 1
- QAWMTMJZJZJODC-UHFFFAOYSA-N CCC(NC1CCN(C)CC1)=O Chemical compound CCC(NC1CCN(C)CC1)=O QAWMTMJZJZJODC-UHFFFAOYSA-N 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N C[n]1cccc1 Chemical compound C[n]1cccc1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N C[n]1cncc1 Chemical compound C[n]1cncc1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- XBOCMRIDGWVTQR-UHFFFAOYSA-N NC(C(CC1)CCN1N)=O Chemical compound NC(C(CC1)CCN1N)=O XBOCMRIDGWVTQR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793113P | 2013-03-15 | 2013-03-15 | |
| US61/793,113 | 2013-03-15 | ||
| EP14305361.9 | 2014-03-13 | ||
| EP14305361 | 2014-03-13 | ||
| PCT/US2014/029270 WO2014144737A1 (en) | 2013-03-15 | 2014-03-14 | Heteroaryl compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519673A JP2016519673A (ja) | 2016-07-07 |
| JP2016519673A5 true JP2016519673A5 (enExample) | 2017-04-20 |
| JP6576325B2 JP6576325B2 (ja) | 2019-09-18 |
Family
ID=50390019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503031A Expired - Fee Related JP6576325B2 (ja) | 2013-03-15 | 2014-03-14 | ヘテロアリール化合物およびそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9663524B2 (enExample) |
| EP (1) | EP2968337B1 (enExample) |
| JP (1) | JP6576325B2 (enExample) |
| KR (1) | KR102219695B1 (enExample) |
| CN (2) | CN111793068A (enExample) |
| AU (1) | AU2014228746B2 (enExample) |
| BR (1) | BR112015022191A8 (enExample) |
| EA (1) | EA036160B1 (enExample) |
| MA (1) | MA38393B1 (enExample) |
| MX (1) | MX374558B (enExample) |
| PE (1) | PE20151776A1 (enExample) |
| SG (1) | SG11201507478VA (enExample) |
| WO (1) | WO2014144737A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| CN105683188B (zh) | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| WO2016014551A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| CA2954186A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| EP3177295A4 (en) | 2014-08-08 | 2018-06-13 | Dana Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| ES2756748T3 (es) | 2014-10-03 | 2020-04-27 | Novartis Ag | Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| EP3274344B1 (en) | 2015-03-25 | 2019-04-24 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
| CN107660200B (zh) | 2015-04-14 | 2022-01-11 | 卫材R&D管理有限公司 | 结晶fgfr4抑制剂化合物和其用途 |
| JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
| KR20180002053A (ko) * | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| JP7394623B2 (ja) | 2016-11-02 | 2023-12-08 | ノバルティス アーゲー | Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ |
| RU2747260C2 (ru) * | 2016-12-19 | 2021-04-29 | Аббиско Тхерапеутицс Цо., Лтд. | Ингибитор рфрф4, способ его получения и его фармацевтическое применение |
| EP3589284A4 (en) | 2017-02-28 | 2020-12-16 | The General Hospital Corporation | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN110914267B (zh) * | 2017-07-19 | 2022-07-12 | 江苏奥赛康药业有限公司 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
| WO2019029541A1 (zh) * | 2017-08-08 | 2019-02-14 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
| CN109745325B (zh) * | 2017-11-08 | 2022-02-15 | 上海翰森生物医药科技有限公司 | Fgfr4抑制剂、其制备方法和用途 |
| CN110386921A (zh) * | 2018-04-23 | 2019-10-29 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂化合物 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| WO2019223766A1 (zh) * | 2018-05-25 | 2019-11-28 | 上海和誉生物医药科技有限公司 | 一种fgfr抑制剂、其制备方法和在药学上的应用 |
| CN110577524B (zh) * | 2018-06-07 | 2022-01-28 | 北京大学深圳研究生院 | 一种激酶选择性抑制剂 |
| WO2019242587A1 (zh) * | 2018-06-19 | 2019-12-26 | 上海和誉生物医药科技有限公司 | 一种高选择性FGFR i抑制剂及其制备方法和应用 |
| WO2020052349A1 (zh) | 2018-09-14 | 2020-03-19 | 上海和誉生物医药科技有限公司 | Fgfr抑制剂、其制备方法和应用 |
| EP3902805A4 (en) | 2018-12-28 | 2023-03-01 | SPV Therapeutics Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
| WO2020177067A1 (en) * | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| EP3936509B1 (en) * | 2019-03-08 | 2024-07-31 | Shouyao Holdings (Beijing) Co., Ltd. | Fgfr4 kinase inhibitor, preparation method therefor and use thereof |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102333854B1 (ko) | 2019-10-24 | 2021-12-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| GB201915828D0 (en) * | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR102382613B1 (ko) * | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2021436754B2 (en) * | 2021-03-26 | 2024-11-07 | Apeloa Pharmaceutical Co., Ltd. | Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN113527311B (zh) * | 2021-08-23 | 2022-05-06 | 中南大学湘雅医院 | Fgfr4抑制剂、组合物及其在药物制备中的用途 |
| WO2023039828A1 (en) * | 2021-09-17 | 2023-03-23 | Nutshell Biotech (Shanghai) Co., Ltd. | Fused ring compounds as inhibitors of fgfr4 tyrosine kinases |
| CN113912602B (zh) * | 2021-10-14 | 2023-05-05 | 温州医科大学 | 一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途 |
| WO2024199388A1 (zh) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| EP4509142A1 (en) | 2023-08-16 | 2025-02-19 | Ona Therapeutics S.L. | Fgfr4 as target in cancer treatment |
| CN120775123A (zh) * | 2025-09-12 | 2025-10-14 | 怀化市恒渝新材料有限公司 | 一种光引发剂制备方法、光引发剂及其应用 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| FI971953A7 (fi) * | 1994-11-14 | 1997-05-12 | Warner Lambert Co | Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| ES2301194T3 (es) * | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| DE19802377A1 (de) | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| PL347432A1 (en) | 1998-10-23 | 2002-04-08 | Hoffmann La Roche | Bicyclic nitrogen heterocycles |
| JP2003509425A (ja) | 1999-09-15 | 2003-03-11 | ワーナー−ランバート・カンパニー | キナーゼ阻害剤としてのプテリジノン |
| DE60033307T2 (de) | 1999-10-21 | 2007-07-12 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen als p38-proteinkinase-inhibitoren |
| ATE349447T1 (de) | 1999-10-21 | 2007-01-15 | Hoffmann La Roche | Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren |
| AR030053A1 (es) | 2000-03-02 | 2003-08-13 | Smithkline Beecham Corp | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
| JP2004519422A (ja) | 2000-08-04 | 2004-07-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン |
| KR100571339B1 (ko) | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| US6518276B2 (en) | 2000-08-31 | 2003-02-11 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (II) |
| JP4146721B2 (ja) | 2000-08-31 | 2008-09-10 | エフ．ホフマン−ラ ロシュ アーゲー | ７−オキソ−ピリドピリミジン類 |
| US6506749B2 (en) | 2000-08-31 | 2003-01-14 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (I) |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| WO2004014869A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| TW200413381A (en) | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| US7129351B2 (en) | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| BR0317430A (pt) | 2002-12-20 | 2005-10-25 | Pharmacia Corp | Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2004063195A1 (en) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| CA2521124A1 (en) | 2003-04-10 | 2004-10-21 | F. Hoffmann-La Roche Ag | Pyrimido compounds |
| RU2356896C2 (ru) | 2003-04-16 | 2009-05-27 | Ф.Хоффманн-Ля Рош Аг | Производные хиназолина |
| AU2004260689B8 (en) | 2003-07-29 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005034869A2 (en) | 2003-10-08 | 2005-04-21 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005066211A2 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| JP5520433B2 (ja) | 2004-01-21 | 2014-06-11 | エモリー ユニバーシティー | 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用 |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US20090118261A1 (en) | 2004-08-31 | 2009-05-07 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| WO2006024486A2 (en) | 2004-08-31 | 2006-03-09 | F. Hoffmann-La Roche Ag | Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| EP1789417A1 (en) | 2004-08-31 | 2007-05-30 | F.Hoffmann-La Roche Ag | AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7767687B2 (en) | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| AU2006257859B2 (en) | 2005-06-10 | 2009-12-10 | Irm Llc | Compounds that maintain pluripotency of embryonic stem cells |
| WO2006137421A1 (ja) | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 局所投与剤 |
| NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| EP1906967A4 (en) | 2005-07-26 | 2010-07-28 | Vertex Pharma | ABL Kinase Inhibition |
| KR100832593B1 (ko) * | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| ME00011A (me) | 2005-12-21 | 2009-02-10 | Novartis Ag | Derivati pirimidinilaril uree kao fgf inhibitori |
| WO2007075783A2 (en) | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
| PL2027123T3 (pl) * | 2006-05-11 | 2011-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| JP2009537520A (ja) | 2006-05-15 | 2009-10-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法 |
| BRPI0715566A2 (pt) | 2006-10-16 | 2013-07-02 | Gpc Biotech Inc | composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto |
| WO2008150260A1 (en) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| US8129659B2 (en) | 2006-10-20 | 2012-03-06 | Swagelok Company | Apparatus having DC arc start in parallel with welder power supply |
| WO2008055842A1 (en) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| EP2102164B1 (en) * | 2006-12-27 | 2010-12-01 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
| ATE502027T1 (de) * | 2006-12-27 | 2011-04-15 | Sanofi Aventis | Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren |
| PL2168966T3 (pl) | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| US8216783B2 (en) | 2008-04-14 | 2012-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| US20110039845A1 (en) | 2008-04-23 | 2011-02-17 | Kyowa Hakko Kirin Co., Ltd. | 2-aminoquinazoline derivative |
| AU2009248774B2 (en) * | 2008-05-23 | 2012-05-31 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| JP2012501654A (ja) * | 2008-09-05 | 2012-01-26 | アビラ セラピューティクス， インコーポレイテッド | 不可逆的インヒビターの設計のためのアルゴリズム |
| CA2745970A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| EP2376494A4 (en) | 2008-12-12 | 2012-07-11 | Msd Kk | DIHYDROPYRIMIDOPYRIMIDINDERIVATE |
| EP2379559B1 (en) | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| CN102713618B (zh) * | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| US20120258940A1 (en) | 2009-12-18 | 2012-10-11 | Giordano Caponigro | Method for treating haematological cancers |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| CN103501610A (zh) * | 2011-03-09 | 2014-01-08 | 西建阿维拉米斯研究公司 | Pi3激酶抑制剂和其用途 |
| CA2828890A1 (en) * | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
| DK2710007T3 (da) | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | Kinasehæmmere |
| CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
| BR112014010631A2 (pt) | 2011-11-04 | 2017-04-25 | Afraxis Holdings Inc | inibidores de pak para o tratamento da síndrome do x frágil |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| KR101652229B1 (ko) | 2012-06-07 | 2016-08-30 | 데시페라 파마슈티칼스, 엘엘씨. | 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물 |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| EP3628749A1 (en) | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
| WO2015017528A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Pik3c2g fusions |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
-
2014
- 2014-03-14 MA MA38393A patent/MA38393B1/fr unknown
- 2014-03-14 SG SG11201507478VA patent/SG11201507478VA/en unknown
- 2014-03-14 MX MX2015011514A patent/MX374558B/es active IP Right Grant
- 2014-03-14 US US14/776,373 patent/US9663524B2/en active Active
- 2014-03-14 CN CN202010661205.XA patent/CN111793068A/zh active Pending
- 2014-03-14 EA EA201591420A patent/EA036160B1/ru not_active IP Right Cessation
- 2014-03-14 EP EP14763001.6A patent/EP2968337B1/en active Active
- 2014-03-14 PE PE2015002022A patent/PE20151776A1/es unknown
- 2014-03-14 AU AU2014228746A patent/AU2014228746B2/en not_active Ceased
- 2014-03-14 JP JP2016503031A patent/JP6576325B2/ja not_active Expired - Fee Related
- 2014-03-14 CN CN201480016170.7A patent/CN105307657B/zh not_active Expired - Fee Related
- 2014-03-14 BR BR112015022191A patent/BR112015022191A8/pt active Search and Examination
- 2014-03-14 KR KR1020157029048A patent/KR102219695B1/ko not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/029270 patent/WO2014144737A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115843272B (zh) | Nek7激酶的抑制剂 | |
| ES2928169T3 (es) | Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos | |
| RU2521394C2 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
| CN102264725B (zh) | 蛋白激酶抑制剂 | |
| Bayomi et al. | Synthesis and biological evaluation of new curcumin analogues as antioxidant and antitumor agents: molecular modeling study | |
| JP6139782B2 (ja) | 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物 | |
| JP2016053042A5 (enExample) | ||
| CA3102214A1 (en) | Ligands to cereblon (crbn) | |
| US9550738B2 (en) | Bicyclic compounds as kinases inhibitors | |
| JP2013506715A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2011500685A5 (enExample) | ||
| JP7319977B2 (ja) | チューブリン阻害剤 | |
| ES2987563T3 (es) | Moduladores del receptor de glucocorticoides ciclohexenilo pirimidina | |
| TW202012404A (zh) | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 | |
| JP2013504325A5 (enExample) | ||
| CN106905297A (zh) | 用于脑癌的新颖治疗剂 | |
| US20070248692A1 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| MX2015000101A (es) | Compuestos y usos terapéuticos de los mismos. | |
| TN2015000529A1 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| Nguyen et al. | Design, synthesis, and pharmacological evaluation of second-generation tetrahydroisoquinoline-based CXCR4 antagonists with favorable ADME properties | |
| US12440494B2 (en) | Compounds useful for inhibiting RAF dimers | |
| EA201400595A1 (ru) | Морфолинилбензотриазины для применения в лечении рака | |
| CY1118559T1 (el) | 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak | |
| WO2017041040A1 (en) | Androgen receptor antagonists |